Pfizer's Xeljanz elected in US as 1st JAK in RA

The US FDA on 6 November sanctioned pharma giant Pfizer's Xeljanz (tofacitinib citrate) as a treatment for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or are intolerant to methotrexate – granting the approval two weeks ahead of the medicine's action goal date.

The US FDA on 6 November sanctioned pharma giant Pfizer's Xeljanz (tofacitinib citrate) as a treatment for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or are intolerant to methotrexate – granting the approval two weeks ahead of the medicine's action goal date.

The drug is the first Janus kinase (JAK) inhibitor approved for RA – only the second JAK inhibitor to gain...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category